Turnstone Biologics Corp. (TSBX)
- Previous Close
2.9000 - Open
2.8800 - Bid 2.7000 x 100
- Ask 2.8300 x 100
- Day's Range
2.7400 - 3.0400 - 52 Week Range
1.6250 - 13.2000 - Volume
129,466 - Avg. Volume
168,126 - Market Cap (intraday)
63.835M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.7800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.00
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
turnstonebio.comRecent News: TSBX
Performance Overview: TSBX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TSBX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TSBX
Valuation Measures
Market Cap
63.83M
Enterprise Value
-27.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.65
Price/Book (mrq)
0.65
Enterprise Value/Revenue
-1.44
Enterprise Value/EBITDA
0.49
Financial Highlights
Profitability and Income Statement
Profit Margin
-285.92%
Return on Assets (ttm)
-32.34%
Return on Equity (ttm)
-65.27%
Revenue (ttm)
19.31M
Net Income Avi to Common (ttm)
-55.24M
Diluted EPS (ttm)
-4.7800
Balance Sheet and Cash Flow
Total Cash (mrq)
94.78M
Total Debt/Equity (mrq)
3.26%
Levered Free Cash Flow (ttm)
-45.82M